[Retracted] Antenatal Steroid Therapy for Fetal Lung Maturation and the Subsequent Risk of Childhood Asthma: A Longitudinal Analysis

Table 3

Association between antenatal steroid therapy exposure and childhood asthma.

	Adjusted		Unadjusted
	HR	95% CI	HR	95% CI
Antenatal steroid exposure
3–5 years	1.19	1.03–1.39	1.55	1.36–1.77
6–7 years	1.06	0.86–1.30	1.36	1.12–1.65
8+ years	0.74	0.54–1.03	0.98	0.72–1.34
Male gender	1.24	1.21–1.28	—
Preterm birth (<37 weeks)	1.03	0.95–1.12	—
Number of siblings
0	1.00	—
1	0.90	0.88–0.93	—
2	0.78	0.74–0.82	—
3+	0.67	0.62–0.72	—
Bronchopulmonary Dysplasia	0.98	0.74–1.31	—
Hyaline Membrane Disease	1.14	1.01–1.30	—
Surfactant Administration	1.07	0.82–1.40	—
1 Minute Apgar Score
0–3	1.00	—
4–6	0.95	0.86–1.05	—
7–10	0.87	0.79–0.95	—
Caesarean section	1.11	1.07–1.15	—
Maternal smoking	1.12	1.09–1.16	—
Birth weight (per 500 grams)	1.00	0.98–1.01	—
Gestational age (weeks)	0.97	0.96–0.98	—
Birth year
1989	1.47	1.37–1.59
1990	1.45	1.35–1.56	—
1991	1.49	1.39–1.60	—
1992	1.28	1.19–1.37	—
1993	1.21	1.12–1.30	—
1994	1.14	1.06–1.23	—
1995	1.12	1.04–1.20	—
1996	0.99	0.92–1.07	—
1997	1.02	0.95–1.11	—
1998	1.00	—

Note: Adjustment for all other confounders in table.